Amgen Inc. $AMGN Shares Acquired by Global X Japan Co. Ltd.

Global X Japan Co. Ltd. grew its stake in Amgen Inc. (NASDAQ:AMGN) by 5,554.2% during the third quarter, Holdings Channel.com reports. The fund owned 4,693 shares of the medical research company’s stock after acquiring an additional 4,610 shares during the period. Global X Japan Co. Ltd.’s holdings in Amgen were worth $1,324,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in AMGN. Brighton Jones LLC raised its position in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the period. Caisse DE Depot ET Placement DU Quebec lifted its stake in Amgen by 43.1% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 213,177 shares of the medical research company’s stock worth $66,415,000 after acquiring an additional 64,253 shares in the last quarter. PKS Advisory Services LLC boosted its holdings in Amgen by 6.1% during the 1st quarter. PKS Advisory Services LLC now owns 1,669 shares of the medical research company’s stock valued at $519,000 after acquiring an additional 96 shares during the period. Warwick Investment Management Inc. grew its position in Amgen by 21.8% in the 1st quarter. Warwick Investment Management Inc. now owns 955 shares of the medical research company’s stock valued at $298,000 after acquiring an additional 171 shares in the last quarter. Finally, Ieq Capital LLC increased its stake in Amgen by 43.8% during the first quarter. Ieq Capital LLC now owns 51,541 shares of the medical research company’s stock worth $16,058,000 after purchasing an additional 15,711 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 in the last three months. 0.69% of the stock is currently owned by company insiders.

Amgen Trading Up 0.0%

NASDAQ AMGN opened at $331.49 on Wednesday. The firm’s fifty day moving average price is $320.86 and its 200 day moving average price is $300.89. Amgen Inc. has a 12 month low of $257.05 and a 12 month high of $346.38. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The company has a market capitalization of $178.50 billion, a price-to-earnings ratio of 25.62, a price-to-earnings-growth ratio of 3.08 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period last year, the business earned $5.58 EPS. Amgen’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent research reports. Truist Financial began coverage on shares of Amgen in a research note on Monday, November 24th. They issued a “hold” rating and a $318.00 price objective for the company. Raymond James Financial began coverage on shares of Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating for the company. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Amgen in a research report on Tuesday, November 25th. BMO Capital Markets lifted their target price on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average price target of $332.85.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive clinical update — Amgen reported progress in its pediatric inebilizumab study, highlighting potential long‑term upside in a rare autoimmune indication that could expand future revenue and orphan pricing opportunities. Article Title
• Positive Sentiment: Pipeline durability — Amgen extended its long‑term pediatric psoriasis study for apremilast, signaling continued commitment to pediatric indications and increasing the value of its dermatology franchise. Article Title
• Positive Sentiment: Analyst sentiment supportive — Amgen received a consensus “Moderate Buy” from analysts, which can buoy inflows and help sustain multiple expansion given solid earnings and guidance history. Article Title
• Positive Sentiment: Included in “top drug stocks” narratives — industry write‑ups placing Amgen among big drugmakers positioned to outperform in 2026 raise visibility and may attract momentum investors. Article Title
• Positive Sentiment: Market performance note — coverage highlighting that Amgen is outpacing broader market gains reinforces a bullish technical/flow narrative among investors. Article Title
• Positive Sentiment: Index/leadership focus — commentary on Amgen’s biotechnology leadership and index positioning can support passive inflows and institutional demand. Article Title
• Neutral Sentiment: Competitive comparison — a sector piece comparing Novo Nordisk and Amgen frames AMGN more as a diversified biologics/pipeline play versus GLP‑1 leaders; useful for allocation decisions but not an immediate catalyst. Article Title
• Neutral Sentiment: Policy/deal with U.S. administration — reports that Amgen joined other firms in a drug‑pricing deal with the administration create mixed implications (pricing headwinds vs. tariff/incentive benefits and regulatory certainty). Investors will watch the net financial terms. Article Title

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.